LAUSANNE, Switzerland, January 4, 2018 /PRNewswire/ -- Oculis (www.oculis.com), a clinical-stage biotechnology company focused on the development of breakthrough non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing...
from PR Newswire: //www.prnewswire.co.uk/news-releases/oculis-raises-chf20-million-in-a-series-b-financing-round-to-advance-breakthrough-treatments-for-667996983.html
No comments:
Post a Comment